HRX 22 - GPX Inc. CEO Javier Echenique (GPX Inc., Boston, MA, US) joins us to discuss CardioID - a novel AI Algorithm-based "bloodless blood test" that uses NT-proBNP biomarkers in patient monitoring for heart failure decompensation. The TRIBE-HF 2 study is currently underway for algorithm training and validation.
1. What are the clinical unmet needs in heart failure that led to the creation of this technology?
2. What is CardioID?
3. What is the data underpinning the use of this technology, and what future study is planned?
4. How can this technology aid both patients and clinicians in daily practice?
5. Where do you see the future directions of CardioID headed?
Recorded Remotely from Barcelona, 2022.
Interviewer: Jordan Rance